Literature DB >> 15977417

The pharmacogenetics of asthma: an update.

Kelan G Tantisira1, Scott T Weiss.   

Abstract

Responses to the three major classes of asthma therapy, beta-agonists, leukotriene antagonists and inhaled corticosteroids, demonstrate wide inter-individual variability. Moreover, both asthma and the traits measured in response to asthma therapy, including forced expiratory volume at 1 s, are highly heritable. This indicates that genetics may play a prominent role in the determination of the therapeutic response to asthma. The human genetic association trials that investigate responses to each of the three major classes of asthma therapy will be summarized, and recent findings in the literature highlighted. Altogether, the available data indicate that genetics influences the likelihood of an individual responding to a given therapy, indicating that, in the future, optimal care for individuals with asthma may include genetic testing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15977417

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  8 in total

1.  A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulation.

Authors:  Xiaofeng Jiang; Hui Pan; Joseph F Nabhan; Ramaswamy Krishnan; Cynthia Koziol-White; Reynold A Panettieri; Quan Lu
Journal:  FASEB J       Date:  2012-01-25       Impact factor: 5.191

Review 2.  Asthma from a pharmacogenomic point of view.

Authors:  C Szalai; I Ungvári; L Pelyhe; G Tölgyesi; A Falus
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

3.  Influence of leukotriene pathway polymorphisms on response to montelukast in asthma.

Authors:  John J Lima; Shu Zhang; Audrey Grant; Lianhe Shao; Kelan G Tantisira; Hooman Allayee; Jianwei Wang; James Sylvester; Janet Holbrook; Robert Wise; Scott T Weiss; Kathleen Barnes
Journal:  Am J Respir Crit Care Med       Date:  2005-11-17       Impact factor: 21.405

Review 4.  Expectations, validity, and reality in pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  J Clin Epidemiol       Date:  2009-12-07       Impact factor: 6.437

5.  Pharmacogenetics of asthma in children.

Authors:  Naomi Kondo; Eiko Matsui; Akane Nishimura; Hideo Kaneko
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

Review 6.  Integrative systems biology approaches in asthma pharmacogenomics.

Authors:  Amber Dahlin; Kelan G Tantisira
Journal:  Pharmacogenomics       Date:  2012-09       Impact factor: 2.533

7.  Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program.

Authors:  Sunita Sharma; Augusto A Litonjua; Kelan G Tantisira; Anne L Fuhlbrigge; Stanley J Szefler; Robert C Strunk; Robert S Zeiger; Amy J Murphy; Scott T Weiss
Journal:  J Allergy Clin Immunol       Date:  2008-10-10       Impact factor: 10.793

8.  ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study.

Authors:  Jill M Ferdinands; David M Mannino; Marta L Gwinn; Molly S Bray
Journal:  PLoS One       Date:  2007-03-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.